CIMA rejects Cephalon bid
Executive Summary
Cephalon's proposal to acquire CIMA at $26 per share does not represent a superior offer to CIMA's proposed merger with aaiPharma, CIMA says Sept. 2. Company received unsolicited takeover bid from Cephalon following announcement of proposed merger with aaiPharma; CIMA was prohibited from entering negotiations with Cephalon unless its board deemed the offer superior to merger plans (1"The Pink Sheet" Aug. 25, 2003, p. 17)...
You may also be interested in...
CIMA negotiations with Cephalon
CIMA reopens negotiations with Cephalon on a proposed merger. CIMA's board previously deemed a bid made by Cephalon of $26 per share insufficient to break CIMA's proposed merger with aaiPharma (1"The Pink Sheet" Sept. 8, 2003, In Brief). Cephalon has presumably increased its offer. CIMA and aaiPharma announced a proposed merger Aug. 5; Cephalon then made an unsolicited takeover bid...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.